Allogene Therapeutics Inc (NAS:ALLO)
$ 2.02 -0.12 (-5.61%) Market Cap: 448.70 Mil Enterprise Value: 252.75 Mil PE Ratio: 0 PB Ratio: 0.91 GF Score: 36/100

Allogene Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 01, 2021 / 02:30PM GMT
Release Date Price: $25.37 (-1.28%)
Michael Jonathan Yee
Jefferies LLC, Research Division - Equity Analyst

Well, good morning, everyone, and welcome to another great session here at the 2021 Jefferies Global Healthcare Conference. I'm really excited to have my first fireside chat with Allogene Therapeutics. With us here, we have the Co-Founder, President and CEO, David Chang.

Now importantly, he just came off a really important data, preempting that ASCO conference what was important data. So maybe we could just take a step back, David, and maybe just talk about the development of 501A as an allogeneic CD19 CAR T and what was so impressive about this data in your mind that should get people excited that you just presented.

Questions & Answers

David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director

First of all, Mike, thank you very much for hosting Allogene. It's been a little while since you and I were in the firechat, so it's a real pleasure to be together again. So given the time consideration, I'm going to be very quick on some of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot